- ICH GCP
- Registr klinických studií v USA
- Klinická studie NCT00513877
Bortezomib in Treating Patients With Malignant Pleural Mesothelioma
An Open Label Phase II Multicentre Clinical Trial of Single Agent Bortezomib in Patients With Malignant Pleural Mesothelioma
RATIONALE: Bortezomib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
PURPOSE: This phase II trial is studying the side effects of bortezomib and how well it works in treating patients with malignant pleural mesothelioma.
Přehled studie
Postavení
Podmínky
Intervence / Léčba
Detailní popis
OBJECTIVES:
Primary
- Assess the clinical efficacy of bortezomib based on the evaluation of objective tumor response rate.
Secondary
- Assess additional clinical efficacy of bortezomib based on the evaluation of time to early disease progression and median overall 2-year survival rate.
- Assess safety and toxicity in these patients.
- Assess quality of life using the Lung Cancer Symptom Score.
OUTLINE: This is a multicenter study. Patients are stratified according to current treatment (first-line vs second-line)
Patients receive bortezomib IV on days 1, 8, 15, and 22. Treatment repeats every 5 weeks for up to 4 courses in the absence of disease progression or unacceptable toxicity. Patients exhibiting objective response or stable disease by week 20, may continue treatment at the discretion of the investigator until evidence of disease progression.
Quality of life is assessed periodically.
After completion of study treatment, patients are followed for up to 2 years.
PROJECTED ACCRUAL: 57 first-line setting and 54 second-line setting patients will be accrued for this study.
Typ studie
Zápis (Aktuální)
Fáze
- Fáze 2
Kontakty a umístění
Studijní místa
-
-
-
Ghent, Belgie, B-9000
- Universitair Ziekenhuis Gent
-
-
-
-
-
Amsterdam, Holandsko, 1066 BE
- Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital
-
-
-
-
-
Cork, Irsko
- Cork University Hospital
-
Dublin, Irsko, 9
- Beaumont Hospital
-
Dublin, Irsko, 7
- Mater Misericordiae University Hospital
-
Dublin, Irsko, 4
- St. Vincent's University Hospital
-
Dublin, Irsko, 24
- Adelaide and Meath Hospital, Dublin Incorporating the National Children's Hospital
-
Dublin, Irsko, 8
- St. James's Hospital
-
Galway, Irsko
- Galway University Hospital
-
-
-
-
England
-
London, England, Spojené království, EC1A 7BE
- Saint Bartholomew's Hospital
-
Sutton, England, Spojené království, SM2 5PT
- Royal Marsden - Surrey
-
-
Northern Ireland
-
Belfast, Northern Ireland, Spojené království, BT9 7BL
- Centre for Cancer Research and Cell Biology at Queen's University Belfast
-
-
Scotland
-
Glasgow, Scotland, Spojené království, G11 6NT
- Beatson West of Scotland Cancer Centre
-
-
Kritéria účasti
Kritéria způsobilosti
Věk způsobilý ke studiu
Přijímá zdravé dobrovolníky
Pohlaví způsobilá ke studiu
Popis
DISEASE CHARACTERISTICS:
Inclusion criteria:
- Histologically confirmed malignant pleural mesothelioma
Meets 1 of the following criteria for first-line or second-line chemotherapy:
- Patients in the first-line setting must be unsuitable for, cannot access locally, or refuse combination chemotherapy
Patients in the second-line setting must be unsuitable for, cannot access locally, or refuse cytotoxic chemotherapy after failure of a first-line regimen
- Second-line patients may not have received more than 1 prior line of antineoplastic treatment for this cancer
Pleural effusions should be drained before treatment whenever possible
- Talc or tetracycline pleurodesis may be used per standard practice for uncontrollable pleural effusions (recurrent despite regular drainage)
Exclusion criteria:
- Symptomatic or known brain or leptomeningeal metastases
PATIENT CHARACTERISTICS:
Inclusion criteria:
- ECOG performance status 0-2
- Hemoglobin ≥ 10 g/dL
- Neutrophil count ≥ 1,500 mm^3
- Platelet count ≥ 100,000/mm^3
- Creatinine clearance ≥ 30 mL/min
- AST and ALT < 3 times upper limit of normal
- Fertile patients must use effective contraception during study therapy
Exclusion criteria:
- Pregnant or breastfeeding
- History of prior malignant tumor within the past 3 years except for nonmelanoma skin tumor or carcinoma in situ of the cervix
- Patients suitably fit to receive a platinum doublet based chemotherapy (first-line only)
Uncontrolled or severe cardiovascular disease including any of the following:
- Myocardial infarction within the past 6 months
- New York Heart Association class III or IV heart failure
- Uncontrolled angina
- Clinically significant pericardial disease
- Cardiac amyloidosis
- Neuropathy ≥ grade 2 OR grade 1 with pain
- Serious medical (e.g., uncontrolled diabetes, hepatic disease, or infection) or psychiatric illness that would interfere with study participation
- Patients with known HIV or hepatitis B or C infection
PRIOR CONCURRENT THERAPY:
- No prior bortezomib
- No prior extensive radiation therapy, systemic chemotherapy, or other antineoplastic therapy within 4 weeks before enrollment
- No preplanned surgery or procedures that would interfere with the study
More than 4 weeks since enrollment in another therapeutic clinical trial (i.e., received an experimental drug or used an experimental medical device)
- Concurrent participation in non-treatment studies is allowed provided they do not interfere with participation in this study
No concurrent experimental or antineoplastic agent other than bortezomib
- Medications that may have antineoplastic activity, but are taken for other reasons than specific antineoplastic effect (e.g., megestrol [Megace®], cyclo-oxygenase-2 [COX-2] inhibitors, or bisphosphonates) are allowed
Studijní plán
Jak je studie koncipována?
Detaily designu
- Primární účel: Léčba
- Přidělení: Nerandomizované
- Intervenční model: Přiřazení jedné skupiny
- Maskování: Žádné (otevřený štítek)
Zbraně a zásahy
Skupina účastníků / Arm |
Intervence / Léčba |
---|---|
Experimentální: Bortezomib 1.6mg/m2
|
Co je měření studie?
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
---|---|---|
Objective tumor response rate (complete response or partial response) as assessed by modified RECIST criteria
Časové okno: 28 days prior to baseline, at 10 weeks and at end of treatment
|
The objective tumour response rate is a primary endpoint of the study.
This will be a proportion of evaluable subjects who achieve a confirmed CR or PR per modified RECIST guidelines within four cycles (20 weeks) of treatment.
|
28 days prior to baseline, at 10 weeks and at end of treatment
|
Sekundární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
---|---|---|
Time to disease progression
Časové okno: Time to disease progression is measured from first treatment until the date of PD or death whichever is first reported. Subjects who did not progress or die will be censored at the day of their last tumour assessment.
|
Time to disease progression is measured from first treatment until the date of PD or death whichever is first reported. Subjects who did not progress or die will be censored at the day of their last tumour assessment.
|
|
Overall survival
Časové okno: Overall Survival is measured from the date of first treatment to the date of the subject's death. If the subject is alive or the vital status is unknown, the date of death will be censored at the date that the subject is last known to be alive.
|
Overall Survival is measured from the date of first treatment to the date of the subject's death. If the subject is alive or the vital status is unknown, the date of death will be censored at the date that the subject is last known to be alive.
|
|
Safety
Časové okno: The assessment of safety will be based mainly on the frequency of adverse events and on the number of laboratory values that fall outside of the pre-determined normal ranges.
|
The assessment of safety will be based mainly on the frequency of adverse events and on the number of laboratory values that fall outside of the pre-determined normal ranges.
|
|
Quality of life
Časové okno: Week 1, Week 10 and end of treatment
|
Quality of life will be assessed using the Lung Cancer Symptom Score
|
Week 1, Week 10 and end of treatment
|
Spolupracovníci a vyšetřovatelé
Sponzor
Vyšetřovatelé
- Vrchní vyšetřovatel: Dean A. Fennell, MD, PhD, Centre for Cancer Research and Cell Biology at Queen's University Belfast
Publikace a užitečné odkazy
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia
Primární dokončení (Aktuální)
Termíny zápisu do studia
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Odhad)
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Odhad)
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Více informací
Termíny související s touto studií
Klíčová slova
Další relevantní podmínky MeSH
- Nemoci dýchacích cest
- Novotvary podle histologického typu
- Novotvary
- Plicní onemocnění
- Novotvary podle místa
- Novotvary, žlázové a epiteliální
- Novotvary dýchacího traktu
- Novotvary hrudníku
- Novotvary plic
- Adenom
- Novotvary, mezoteliální
- Pleurální novotvary
- Mezoteliom
- Mezoteliom, maligní
- Antineoplastická činidla
- Bortezomib
Další identifikační čísla studie
- 05-10 ICORG
- ICORG-05-10
- EUDRACT-2005-004420-39
- EU-20748
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .
Klinické studie na hodnocení kvality života
-
Memorial Sloan Kettering Cancer CenterUkončenoRodiny nebo nejbližší příbuzní pacientů léčených v MSKCC pro nekutánní spinocelulární karcinomy | Horní aerodigestivní traktSpojené státy
-
University of MiamiZatím nenabíráme
-
Johns Hopkins UniversityNational Institute on Aging (NIA)DokončenoDelirium | Zlomeniny kyčleSpojené státy
-
Azienda Ospedaliera Universitaria Integrata VeronaNeznámý
-
Dana-Farber Cancer InstituteEMD Serono; National Comprehensive Cancer NetworkNáborRakovina močového měchýře | Uroteliální karcinom | Metastatická rakovina močového měchýře | Neresekabilní karcinom močového měchýřeSpojené státy
-
Bursa Yüksek İhtisas Education and Research HospitalDokončenoPooperační nevolnost a zvracení | ŽvýkačkaKrocan
-
Centre Hospitalier Universitaire de Saint EtienneMinistry of Health, FranceNábor
-
University Hospital, ToulouseNáborCévní mozková příhodaFrancie
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)NáborNemalobuněčný karcinom plic | Stav výkonuSpojené státy